|
1
|
Duncan M and Grant G: Oral and intestinal
mucositis-causes and possible treatments. Aliment Pharmacol Ther.
18:853–874. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Burdelya LG, Gleiberman AS, Toshkov I,
Aygun-Sunar S, Bapardekar M, Manderscheid-Kern P, Bellnier D,
Krivokrysenko VI, Feinstein E and Gudkov AV: Toll-like receptor 5
agonist protects mice from dermatitis and oral mucositis caused by
local radiation: Implications for head-and-neck cancer
radiotherapy. Int J Radiat Oncol Biol Phys. 83:228–234. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sonis ST: Oral mucositis. Anticancer
Drugs. 22:607–612. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
McCarthy GM, Awde JD, Ghandi H, Vincent M
and Kocha WI: Risk factors associated with mucositis in cancer
patients receiving 5-fluorouracil. Oral Oncol. 34:484–490. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Miyano K, Ueno T, Yatsuoka W and Uezono Y:
Treatment for cancer patients with oral mucositis: Assessment based
on the mucositis study group of the multinational association of
supportive care in cancer in international society of oral oncology
(MASCC/ISOO) in 2013 and proposal of possible novel treatment with
a Japanese herbal medicine. Curr Pharm Des. 22:2270–2278. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lalla RV, Sonis ST and Peterson DE:
Management of oral mucositis in patients who have cancer. Dent Clin
North Am. 52:61–77. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Skubitz KM: Glutamine as a potential
treatment for the prevention of chemotherapy induced mucositis. J
Infusional Chemotherapy. 4:64–67. 1994.
|
|
8
|
Kyllo RL and Anadkat MJ: Dermatologic
adverse events to chemotherapeutic agents, part 1: Cytotoxics,
epidermal growth factor receptors, multikinase inhibitors, and
proteasome inhibitors. Semin Cutan Med Surg. 33:28–39. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Shou J, Lieberman MD, Hofmann K, Leon P,
Redmond HP, Davies H and Daly JM: Dietary manipulation of
methotrexate-induced enterocolitis. JPEN J Parenter Enteral Nutr.
15:307–312. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Campos MI, Campos CN, Aarestrup FM and
Aarestrup BJ: Oral mucositis in cancer treatment: Natural history,
prevention and treatment. Mol Clin Oncol. 2:337–340. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Keefe DM, Schubert MM, Elting LS, Sonis
ST, Epstein JB, Raber-Durlacher JE, Migliorati CA, McGuire DB,
Hutchins RD, Peterson DE, et al: Updated clinical practice
guidelines for the prevention and treatment of mucositis. Cancer.
109:820–831. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Peterson DE, Bensadoun RJ and Roila F;
ESMO Guidelines Working Group, : Management of oral and
gastrointestinal mucositis: ESMO clinical recommendations. Ann
Oncol. 20 (Suppl 4):S174–S177. 2009. View Article : Google Scholar
|
|
13
|
Quinn B, Potting CM, Stone R, Blijlevens
NM, Fliedner M, Margulies A and Sharp L: Guidelines for the
assessment of oral mucositis in adult chemotherapy, radiotherapy
and haematopoietic stem cell transplant patients. Eur J Cancer.
44:61–72. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Henke M, Alfonsi M, Foa P, Giralt J,
Bardet E, Cerezo L, Salzwimmer M, Lizambri R, Emmerson L, Chen MG
and Berger D: Palifermin decreases severe oral mucositis of
patients undergoing postoperative radiochemotherapy for head and
neck cancer: A randomized, placebo-controlled trial. J Clin Oncol.
29:2815–2820. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bensinger W, Schubert M, Ang KK, Brizel D,
Brown E, Eilers JG, Elting L, Mittal BB, Schattner MA, Spielberger
R, et al: NCCN Task force report. Prevention and management of
mucositis in cancer care. J Natl Compr Canc Netw. 6 (Suppl
1):S1–S21; quiz S22-S24. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Svanberg A, Ohrn K and Birgegard G: Oral
cryotherapy reduces mucositis and improves nutrition-a randomised
controlled trial. J Clin Nurs. 19:2146–2151. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Scully C, Epstein J and Sonis S: Oral
mucositis: A challenging complication of radiotherapy,
chemotherapy, and radiochemotherapy. Part 2: Diagnosis and
management of mucositis. Head Neck. 26:77–84. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Cowen D, Tardieu C, Schubert M, Peterson
D, Resbeut M, Faucher C and Franquin JC: Low energy Helium-Neon
laser in the prevention of oral mucositis in patients undergoing
bone marrow transplant: Results of a double blind randomized trial.
Int J Radiat Oncol Biol Phys. 38:697–703. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Online EA Pharma Co., Ltd. Products
Information, Elental®, . simplehttp://www.eapharma.co.jp/medicalexpert/product/elental/elental_information.htmlWebpage
in Japanese. July 25–2019
|
|
20
|
Yamamoto T, Nakahigashi M, Umegae S,
Kitagawa T and Matsumoto K: Impact of elemental diet on mucosal
inflammation in patients with active Crohn's disease: Cytokine
production and endoscopic and histological findings. Inflamm Bowel
Dis. 11:580–588. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Johtatsu T, Andoh A, Kurihara M, Iwakawa
H, Tsujikawa T, Kashiwagi A, Fujiyama Y and Sasaki M: Serum
concentrations of trace elements in patients with Crohn's disease
receiving enteral nutrition. J Clin Biochem Nutr. 4:197–201. 2007.
View Article : Google Scholar
|
|
22
|
Yamamoto T, Nakahigashi M, Saniabadi AR,
Iwata T, Maruyama Y, Umegae S and Matsumoto K: Impacts of long-term
enteral nutrition on clinical and endoscopic disease activities and
mucosal cytokines during remission in patients with Crohn's
disease: A prospective study. Inflamm Bowel Dis. 13:1493–1501.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hanai H, Iida T, Takeuchi K, Arai H, Arai
O, Abe J, Tanaka T, Maruyama Y, Ikeya K, Sugimoto K, et al:
Nutritional therapy versus 6-mercaptopurine as maintenance therapy
in patients with Crohn's disease. Dig Liver Dis. 44:649–654. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yamamoto T, Nakahigashi M, Umegae S,
Kitagawa T and Matsumoto K: Impact of long-term enteral nutrition
on clinical and endoscopic recurrence after resection for Crohn's
disease: A prospective, non-randomized, parallel, controlled study.
Aliment Pharmacol Ther. 25:67–72. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Fukui T, Itoh Y, Orihara M, Yoshizawa K,
Takeda H, Kawada S and Yoshioka T: Elental prevented and reduced
oral mucositis during chemotherapy in patients esophageal cancer.
Gan To Kagaku Ryoho. 38:2597–2601. 2011.(In Japanese). PubMed/NCBI
|
|
26
|
Ogata Y, Takeuchi M, Ishibashi N, Kibe S,
Takahashi K, Uchida S, Murakami N, Yahara T and Shirouzu K:
Efficacy of Elental on prevention for chemotherapy-induced oral
mucositis in colorectal cancer patients. Gan To Kagaku Ryoho.
39:583–587. 2012.(In Japanese). PubMed/NCBI
|
|
27
|
Harada K, Minami H, Ferdous T, Kato Y,
Umeda H, Horinaga D, Uchida K, Park SC, Hanazawa H, Takahashi S, et
al: The Elental® elemental diet for
chemoradiotherapy-induced oral mucositis: A prospective study in
patients with oral squamous cell carcinoma. Mol Clin Oncol.
10:159–167. 2019.PubMed/NCBI
|
|
28
|
Harada K, Ferdous T, Horinaga D, Uchida K,
Mano T, Mishima K, Park S, Hanazawa H, Takahashi S, Okita A, et al:
Efficacy of elemental diet on prevention for
chemoradiotherapy-induced oral mucositis in patients with oral
squamous cell carcinoma. Support Care Cancer. 24:953–959. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Harada K, Ferdous T, Kobayashi H and
Ueyama Y: Elemental diet accelerates the recovery from oral
mucositis and dermatitis induced by 5-Fluorouracil through the
induction of fibroblast growth factor 2. Integr Cancer Ther.
17:423–430. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Harada K, Ferdous T, Mizukami Y and
Mishima K: Elemental diet inhibits pro-inflammatory cytokine
production in keratinocytes through the suppression of NF-κB
activation. Oncol Rep. 40:361–368. 2018.PubMed/NCBI
|
|
31
|
Luo M, Brooks M and Wicha MS: Asparagine
and Glutamine: Co-conspirators fueling metastasis. Cell Metab.
27:947–949. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Knott SRV, Wagenblast E, Khan S, Kim SY,
Soto M, Wagner M, Turgeon MO, Fish L, Erard N, Gable AL, et al:
Asparagine bioavailability governs metastasis in a model of breast
cancer. Nature. 554:378–381. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Liu H, Ling W, Shen ZY, Jin X and Cao H:
Clinical application of immune-enhanced enteral nutrition in
patients with advanced gastric cancer after total gastrectomy. J
Dig Dis. 13:401–406. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
ASPEN Board of Directors and the Clinical
Guidelines Task Force, . Guidelines for the use of parenteral and
enteral nutrition in adult and pediatric patients. JPEN J Parenter
Enteral Nutr. 26 (Suppl 1):1SA–138SA. 2002. View Article : Google Scholar : PubMed/NCBI
|
